Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3.4% – Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price fell 3.4% on Wednesday . The company traded as low as $6.81 and last traded at $6.88. 4,370,890 shares traded hands during mid-day trading, a decline of 33% from the average session volume of 6,568,276 shares. The stock had previously closed at $7.12.

Analyst Ratings Changes

RXRX has been the subject of several research reports. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Jefferies Financial Group decreased their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Tuesday, September 3rd. Finally, Leerink Partners lowered their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of “Hold” and an average price target of $9.25.

Recursion Pharmaceuticals Trading Down 2.1 %

The stock has a market cap of $1.75 billion, a PE ratio of -3.98 and a beta of 0.85. The firm has a 50-day moving average price of $6.77 and a 200-day moving average price of $7.22. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm’s quarterly revenue was up 147.6% on a year-over-year basis. During the same period last year, the firm posted ($0.43) earnings per share. As a group, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $6.22, for a total transaction of $71,200.34. Following the sale, the director now owns 7,098,428 shares of the company’s stock, valued at $44,152,222.16. This trade represents a 0.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Christopher Gibson sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $6.16, for a total transaction of $123,200.00. Following the transaction, the chief executive officer now directly owns 762,656 shares of the company’s stock, valued at $4,697,960.96. The trade was a 2.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 107,788 shares of company stock worth $724,691 in the last three months. Insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Axxcess Wealth Management LLC lifted its holdings in shares of Recursion Pharmaceuticals by 4.3% during the 3rd quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock valued at $289,000 after buying an additional 1,795 shares during the period. Green Alpha Advisors LLC increased its position in Recursion Pharmaceuticals by 2.9% during the third quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock valued at $427,000 after acquiring an additional 1,800 shares during the last quarter. Interchange Capital Partners LLC increased its position in Recursion Pharmaceuticals by 7.3% during the second quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock valued at $268,000 after acquiring an additional 2,349 shares during the last quarter. Amalgamated Bank lifted its holdings in Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after acquiring an additional 2,459 shares during the period. Finally, Victory Capital Management Inc. boosted its position in Recursion Pharmaceuticals by 13.5% in the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock worth $164,000 after purchasing an additional 2,598 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.